# Correction: Biomimetic proteoglycan nanoparticles for growth factor immobilization and delivery

**Authors:** Nooshin Zandi, Ebrahim Mostafavi, Mohammad Ali Shokrgozar, Elnaz Tamjid, Thomas J. Webster, Nasim Annabi, Abdolreza Simchi

PMC · DOI: 10.1039/d5bm90019k · 2025-03-03

## TL;DR

This paper corrects a previously published study on biomimetic nanoparticles for delivering growth factors.

## Contribution

The correction addresses errors or omissions in the original paper's findings or methodology.

## Key findings

- Errors in the original study's data or methodology are identified and corrected.
- The revised findings ensure accuracy in the reported results on nanoparticle-based growth factor delivery.

## Abstract

Correction for ‘Biomimetic proteoglycan nanoparticles for growth factor immobilization and delivery’ by Nooshin Zandi et al., Biomater. Sci., 2020, 8, 1127–1136, https://doi.org/10.1039/C9BM00668K.

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** Cytotoxicity (MESH:D064420)
- **Chemicals:** DS-PLL (-), PCN (MESH:D011285), DAPI (MESH:C007293), polyelectrolyte (MESH:D000071228)
- **Cell lines:** HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), HS-5 — Homo sapiens (Human), Transformed cell line (CVCL_3720)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11874909/full.md

---
Source: https://tomesphere.com/paper/PMC11874909